ascorbate-glutathione The ascorbate/glutathione cycle The ascorbate–glutathione cycle coming of

N.et al (2025)

36 Results from the Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and T2DM (STRIDE) trial also found that semaglutide 1.0 mg once weekly is associated with an increase in walking distance in individuals with symptomatic peripheral artery disease and T2DM

Telitacicept, a transmembrane activator and cyclophilin ligand interactor (TACI)-Fc fusion protein, has shown significant clinical effects in the treatment of immunoglobulin A nephropathy (IgAN) as demonstrated in a phase II randomized placebo-controlled trial

Ethical Approval This study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments